Why use OneTest™?
It can help with early detection of lung, liver, pancreas, and other cancers that are not widely screened for in the United States.
Broad cancer screening for the most common types of cancer is available in many countries, however, in the US, cancer screening is normally limited to colon cancer, plus breast and cervical cancer for women, and prostate cancer for men. OneTest™ is now available in the US to screen for multiple types of cancers, including lung, liver, pancreatic, ovarian, prostate, kidney and others.
We measure tumor antigens (not genes) which can help detect cancer now, not in the future
Many popular DNA testing companies today offer not only ancestry analysis, but also tests for inherited genetic abnormalities that pre-dispose the consumer to various diseases. Such tests have very limited value for early cancer detection since recent studies have confirmed that fewer than 5% of the genetic mutations that cause cancer are inherited. Instead, most cancer-causing mutations result from random DNA copying errors over time.
Our algorithms provide better accuracy than tumor markers alone.
We use machine learning to compare biomarker levels and other characteristics such as age and gender with a vast database of 28,000 subjects tested over 12 years. This approach has been demonstrated to help detect nearly twice as many cancers as biomarker testing alone. (See Accuracy, Reliability & Scientific Support for more details.)
OneTest™ is powered and validated by real-world data from asymptomatic individuals
Most biomarker-based cancer tests are developed and validated using stored laboratory blood samples from cancer patients. The purported accuracy of these tests usually drops considerably when they are later used in a real-world screening setting (i.e. Individuals without signs or symptoms of cancer).